1. Home
  2. RARE

as 10-07-2025 3:29pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Founded: 2010 Country:
United States
United States
Employees: N/A City: NOVATO
Market Cap: 2.6B IPO Year: 2014
Target Price: $86.64 AVG Volume (30 days): 1.8M
Analyst Decision: Strong Buy Number of Analysts: 14
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -5.52 EPS Growth: N/A
52 Week Low/High: $25.81 - $57.99 Next Earning Date: 11-04-2025
Revenue: $610,159,000 Revenue Growth: 26.77%
Revenue Growth (this year): 19.72% Revenue Growth (next year): 23.29%

Stock Insider Trading Activity of Ultragenyx Pharmaceutical Inc. (RARE)

Name Ticker Relationship Date Transaction AVG Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Parschauer Karah Herdman RARE EVP and Chief Legal Officer Sep 12 '25 Sell $31.17 2,450 $76,366.50 73,271
Huizenga Theodore Alan RARE SVP, Chief Accounting Officer Sep 5 '25 Sell $31.39 84 $2,636.76 50,306

Share on Social Networks: